Publications

Journal Publications


  • Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, Schwartzman S. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017 Aug;34(8):1936-1952. Article PDF

 

Conference Abstracts


  • Craig, G., Knapp, K., Salim, B, Mohan, S., Michalska, M. (2019) Treatment Patterns, Disease Burden and Outcomes in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica Ann Rheum Dis, volume XX, supplement Suppl, year 2019, page AXXX, THU0294 Poster.
  • Craig, G., Knapp, K. (2018) Swollen Joint Count Vs. RAPID3: Why a Discrepancy in Remission State? Arthritis Rheumatol. 2018; 70 (suppl 9) Article.
  • Knapp, K., Craig, G. (2018) In Rheumatoid Arthritis All Disease Activities Are Not Created Equal Arthritis Rheumatol. 2018; 70 (suppl 9) Article.
  • Alemao, E., Ferri, L., Paul, D., Marshall, A., McDonald, L., Rao, A., Anupindi, V. R., Craig, G., Knapp, K. (2018) Prevalence of type 2 diabetes and evaluation of patient characteristics among patients with and without RA from community rheumatology clinics Ann Rheum Dis, volume 77, supplement Suppl, year 2018, page A928, SAT0133 Article
  • Paul, D., McDonald, L., Rao, A., Anupindi, R., Knapp, K. Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics. Arthritis Rheumatol. 2017; 69 (suppl 10).  Article
  • Knapp, K., Mueller, E., Craig, G. Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis. Arthritis Rheumatol. 2017; 69 (suppl 10). Article
  • Lee, D., Mueller, E. Mast Cell Activation Features in Ehlers-Danlos/Joint Hypermobility Patients: A Retrospective Analysis in Light of an Emerging Disease Cluster Arthritis Rheumatol. 2017; 69 (suppl 10). Article
  • Alemao, E., Knapp, K., Anupindi, V., Annamalai, S. Craig, G. (2017). Treatment effects of abatacept and anti-tnf in patients with ra with poor prognostic factors: data from community rheumatology clinics  Article
  • Craig, G., Knapp, K., Ferguson, K., Schwartzman, S. (2016). The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis.  Arthritis & Rheumatism,68(S10 Suppl). Article
  • Schwartzman, S., Knapp, K., Craig, G. (2016). The Importance of Outcome Measures in Ankylosing Spondylitis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Cohort. Arthritis & Rheumatism, 68(S10 Suppl). Article
  • Craig, G., Knapp, K., Ferguson, K., Tavares, R., Bell, M., Schwartzman, S. (2016). Evaluation of a Pre-Assessment Tool to Define the Spectrum of Autoimmune Diseases in an Underserved Environment. Arthritis & Rheumatism, 68(S10 Suppl). Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., (2016). The Importance of Outcome Measures in Rheumatoid Arthritis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Setting. Arthritis & Rheumatism,68(S10 Suppl). Article
  • Wei, W., Knapp, K., Wang, L., Chen, C., Craig, G., Ferguson, K., & Schwartzman, S. (2015). Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis. Arthritis & Rheumatism, 67(S10 Suppl), 3346. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2015). Use of Tofacitinib in a Real World Setting:  Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial. Arthritis & Rheumatism, 67(S10 Suppl), 652-653. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2015). Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting. Arthritis & Rheumatism, 67(S10 Suppl), 3153. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2015). Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman. Arthritis & Rheumatism, 67(S10), 653-654. Article
  • Schwartzman, S., Knapp, K., Craig, G., Ferguson, K., & Kenney, H. (2014). United States Rheumatologists Who Consistently measure Disease Activity In Rheumatoid Arthritis Patients (RA) Are Achieving Low Disease Activity (LDA) and Remission (R). Ann Rheum Dis, 73(Suppl2), AB0290. Article
  • Craig, G., Kenney, H., Knapp, K., & Schwartzman, S. (2013). Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not “Treat To Target” In a Real World Setting. Arthritis & Rheumatism, 64(Suppl2) 2300. Article